Hyeon‐Seok Eom

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Shaji Kumar, Meletios Α. Dimopoulos, Efstathios Kastritis et al. · Leukemia · 2017 · 354 citations · Full text

Medicine, Immunology, Oncology +17

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

Stephen M. Ansell, John Radford, Joseph M. Connors et al. · New England Journal of Medicine · 2022 · 328 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

Alemnew F. Dagnew, Osman İlhan, Won Sik Lee et al. · The Lancet Infectious Diseases · 2019 · 254 citations · Full text

Veterinary Medicine, Immunology, Oncology +16

Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia

Dae‐Young Kim, Young‐Don Joo, Sung-Nam Lim et al. · Blood · 2015 · 184 citations · Full text

Medicine, Oncology, Pharmacology +11

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

Fritz Offner, Olga Samoilova, Evgenii A. Osmanov et al. · Blood · 2015 · 135 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7